https://www.selleckchem.com/pr....oducts/geldanamycin.
Clinical response was defined when 3 of these 4 criteria were fulfilled i) 30% exacerbation decrease; ii) 80% blood eosinophilia reduction; iii) 3 point ACT increase; iv) FEV increase ≥200mL. 83.87% of patients were classified as responsive to MEPO treatment. Substantial depletion of the blood eosinophils (80%) was found in 87.1% of patients, FEV 200mL was seen in 54.84% of patients, a 3-point ACT improvement from baseline was recorded in 80.65% 25 of patients and a 30% reduction of exacerbations rates was seen in 96.77% of
Like
Comment
Share
